Although preclinical stages require the presence of at least one biomarker of AD pathology (either Tau pathology (CSF or PET Tau) or amyloid pathology (CSF Aβ42 or PET amyloid)) and the absence of clinical signs and symptoms [25], several studies have included participants with subjective memory complaints [20,54,57]. This evidence concerns the gene MAPT and amyloidosis.